Denosumab, an inhibitor of RANKL, improves bone mineral density and reduces the incidence of fractures in men who receive androgen deprivation therapy (ADT) for prostate cancer. At present, however, a lack of comparison with potent bisphosphonates limits the assessment of its utility in the prevention of ADT-induced bone loss.
